Sat.Mar 15, 2025 - Fri.Mar 21, 2025

article thumbnail

March 18, 2025: ABATE Infection Analysis Explores Cost-Effectiveness of Strategies to Prevent Hospital-Acquired Infections

Rethinking Clinical Trials

In a cost-effectiveness analysis using data from the ABATE Infection trial, a strategy of chlorhexidine bathing and nasal decolonization targeted to hospitalized adults with medical devices in nonintensive care unit (ICU) settings was cost-effective in reducing hospital-acquired infections. The study results were published this month in JAMA Network Open.

Allergies 144
article thumbnail

Duchenne patient dies after receiving Sarepta gene therapy

Bio Pharma Dive

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the treatment in the future, some analysts wrote.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca and Alteogen agree on ALT-B4 platform tech

Pharmaceutical Technology

AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latters ALT-B4 platform technology.

277
277
article thumbnail

Panel recommends programme for uniform high standard drug regulation nationwide

AuroBlog - Aurous Healthcare Clinical Trials blog

A Parliamentary Panel has recommended implementation of a comprehensive, nationwide and phased Medicines Regulatory Maturity Enhancement Programme on the lines of World Health Organisation’s (WHO) vaccine benchmarking process to ensure a consistently high standard of drug regulation across the country.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

March 20, 2025: iPATH Team Explores Integration of Artificial Intelligence Into Analysis of Qualitative Data

Rethinking Clinical Trials

Dr. Sara Singer, principal investigator for iPATH Researchers from iPATH, an NIH Collaboratory Trial, described key considerations for integrating artificial intelligence tools into analyses of qualitative data. The report was posted this month on the AcademyHealth Blog. The iPATH trial, led by principal investigator Sara Singer at Stanford University, will test the implementation of a practice transformation strategy for type 2 diabetes in federally qualified health centers in California, Massa

article thumbnail

Alnylam drug gets long-awaited FDA approval in deadly heart disease

Bio Pharma Dive

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a competitive and fast-changing market.

More Trending

article thumbnail

Do Ice Baths Really Work? Here’s What The Science Says

AuroBlog - Aurous Healthcare Clinical Trials blog

Do ice baths live up to the hype? (Diana Light/Unsplash) Ice baths have become increasingly popular over the past few years. Fitness enthusiasts and casual exercisers around the world are embracing this trend that was once reserved for elite athletes. Ice baths (also known as “cold water immersion“) are exactly what they sound like.

article thumbnail

Grand Rounds March 14, 2025: Spillover Due to Constraints on Care Delivery: A Potential Source of Bias in Pragmatic Clinical Trials (Sean Mann)

Rethinking Clinical Trials

Speaker Sean Mann Senior Policy Analyst RAND Corporation Slides Keywords Development Economics; Spillover; Bias; Pragmatic Clinical Trials Key Points Individually randomized, parallel-group embedded pragmatic trials randomly assign patients to a new healthcare intervention or to a control group that receives some form of usual care.

article thumbnail

Delayed CDC meeting on vaccines is rescheduled to April

Bio Pharma Dive

A panel of CDC advisers, who had been set to meet in February, will discuss the current measles outbreak as well as guidelines for several types of shots.

Vaccine 260
article thumbnail

Drug Patent Expirations: Unlocking Strategic Investment Opportunities

Drug Patent Watch

Unlocking Strategic Investment Opportunities in the Pharmaceutical Industry As we navigate the ever-evolving landscape of the pharmaceutical industry, one thing remains constant: the expiration of patents on blockbuster medications. These expirations can have a significant impact on the market, creating opportunities for strategic investment and growth.

Drugs 97
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia

Pharmaceutical Technology

Health Canada has granted approval for Biogens Skyclarys to treat Friedreichs ataxia (FA) in individuals aged 16 years and above.

223
223
article thumbnail

Innovating Treg Therapies for ALS and Alzheimer’s with Coya Therapeutics CEO Dr. Arun Swaminathan — Episode 200

XTalks

Join us as we celebrate a major milestone the 200th episode of the Xtalks Life Science Podcast! From groundbreaking biotech innovations to exclusive interviews with life science industry innovators and leaders, we’ve covered it all. Thank you for tuning in each week! We look forward to continuing to bring the latest and greatest across the pharma, biotech and medical industries!

article thumbnail

Stoke CEO exits; Medicare drug price talks advance

Bio Pharma Dive

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.

Drugs 269
article thumbnail

Inside the Russian Pharma Industry: Key Players and Innovations

Drug Patent Watch

Exploring the Russian Pharma Industry: Key Players and Innovations As we continue to navigate the complexities of the global pharmaceutical landscape, it's essential to stay informed about emerging markets and trends. Today, I want to take you on a journey to Russia, a country with a rich history of pharmaceutical innovation and a growing presence in the industry.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

New Publication Shares Insights on Decentralized Clinical Trial Elements in Cancer Trials During the COVID-19 Pandemic

CTTI (Clinical Trials Transformation Initiative)

A new publication from the FDA Oncology Center of Excellence (OCE) and the Clinical Trials Transformation Initiative (CTTI), published in the Clinical Cancer Research journal, provides important insights into how decentralized clinical trial (DCT) elements were used in cancer trials leading to FDA approval during the COVID-19 pandemic. DCT elementssuch as remote monitoring, telemedicine, and home delivery of investigational products were widely used in cancer trials to maintain patient safety an

article thumbnail

Sarepta’s Gene Therapy Elevidys Under Scrutiny After Patient Death

XTalks

A 16-year-old patient died after treatment with Elevidys (delandistrogene moxeparvovec), Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy (DMD). The patient suffered acute liver failure several months after receiving the therapy in December. Liver injury is a known risk with Elevidys and other gene therapies that use adeno-associated viral (AAV) vectors.

article thumbnail

Orca Bio to seek approval of T cell transplant after positive trial data

Bio Pharma Dive

Study results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant in treating certain blood cancers.

Trials 268
article thumbnail

Big tech meets biotech: Recursion and the AI gold rush in pharma 

Pharmaceutical Technology

The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, with a notable acceleration in recent years.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Just 5 Days of Junk Food Can Trigger Obesity’s Hold on Your Brain

AuroBlog - Aurous Healthcare Clinical Trials blog

After a long, stressful day at work, or when pressed for time, the temptation to have a quick, satisfying snack like crisps or a chocolate bar can be strong.

article thumbnail

The End of the Blockbuster Era: Unlocking Growth with Direct-to-Patient Commercialization

Drug Channels

Todays guest post comes from Greg Skalicky, President of EVERSANA. Greg discusses some of the challenges manufacturers face with product commercialization, patient access and adherence, and negotiating partnerships with pharmacy benefit managers (PBMs). He introduces us to EVERSANA DIRECT Commercialization, a direct-to-patient change/model. To learn more about EVERSANA DIRECT Commercialization and how the direct-to-patient model can help you, meet with EVERSANA at the Asembia Summit in Las Vegas

article thumbnail

NGS is changing GxP compliance. Will you adapt?

Bio Pharma Dive

Discover NGS for GxP compliance with full audit trails, operational control and robust data security.

article thumbnail

J&J boosts US operations with $55bn investment

Pharmaceutical Technology

J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Ready or Not, it’s Time to Take AI in Clinical Research Seriously

ACRP blog

Consumers of popular culture in the 1960s and 1970s preferred their artificial intelligence (AI) to come with overtones of danger, if not outright world domination, judging by small- and large-screen science fiction artifacts ranging from episodes of the original Star Trek series to movies like 2001: A Space Odyssey and Colossus: The Forbin Project.

article thumbnail

ICMR to establish Centre for Advanced Research in Aging to explore India-specific biomarkers

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian Council of Medical Research (ICMR) is working to set up a Centre for Advanced Research in Aging, marking a significant move in India’s efforts to address the challenges of aging and age-related diseases.

Research 172
article thumbnail

How biotech and pharma teams are reaching LPI ahead of schedule

Bio Pharma Dive

With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving the impossible.

246
246
article thumbnail

FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease

Pharmaceutical Technology

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Advanced Biomed IPO Raises $6.56M Towards Liquid Biopsy Testing

XTalks

On March 7, 2025, Advanced Biomed Inc. raised $6.56 million in its IPO and began trading on Nasdaq under the ticker ADVB. The biotech firm, which develops semiconductor-based microfluidic technology for early cancer detection, issued 1.64 million shares at $4 each, with an option to purchase an additional 246,000 shares within 45 days. Current Share Price: Established in 2014, Advanced Biomed has developed a proprietary microfluidic platform that functions as a compact laboratory on a chip.

article thumbnail

Looking at Images of Nature Does Something Powerful in The Brain

AuroBlog - Aurous Healthcare Clinical Trials blog

(Ippei Naoi/Getty Images) Simply looking at nature or even just digital pictures of it can relieve pain, according to new research which scanned the brains of people receiving electrical shocks. Nature’s many health benefits have been documented by decades of research.

Research 147
article thumbnail

J&J boosts US manufacturing as big pharma reshores

Bio Pharma Dive

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

article thumbnail

Menarini to enhance BPDCN detection with VisualDx’s link

Pharmaceutical Technology

Menarini Group has announced a partnership with VisualDx to enhance the diagnosis of individuals with BPDCN.

180
180
article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.